Apart from the polypeptidic nanoparticle structure, the constitutive overexpression of the CXCR4 receptor in many available DLBCL cell lines 23,35 and around 30-50% of malignant B-cell lymphocytes derived from DLBCL patients 23,36 allows to achieve a highly selective elimination of aggressive-lymphoma cells by this CXCR4-targeted nanoparticle. This evidence concerns the gene CXCR4 and lymphoma.